Ipamorelin

A selective growth hormone secretagogue with a clean stimulation profile and minimal side effects at research doses.

Ipamorelin is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.

Sourcing for research purposes? Get 50% off at Ascension Peptides.

Shop now →

What it is

Ipamorelin is a pentapeptide (5 amino acids) and selective growth hormone releasing peptide (GHRP). It stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) in the pituitary gland.

What distinguishes Ipamorelin from other GHRPs is its selectivity — it produces a more targeted GH pulse without significantly elevating cortisol or prolactin, which are common concerns with older GHRPs like GHRP-6.

What research shows

Selective GH pulse stimulation without cortisol or prolactin elevation at research doses
Increased IGF-1 levels in animal models
Improved bone density in some animal studies
Potential fat oxidation effects via GH elevation
Synergistic GH release when paired with CJC-1295

What remains unknown

Optimal long-term dosing protocols in humans
Full safety profile with extended human use
Comparative GH release versus other secretagogues in humans specifically

Administration basics

Common use cases

GH optimization, body composition, recovery, longevity protocols. Almost always stacked with CJC-1295.

Half-life

~2 hours.

Administration

Subcutaneous injection. Typically dosed 2–3x daily or before sleep.

Source this compound

Looking for Ipamorelin?

Use this link to get 50% off your order at Ascension Peptides — discount applied automatically at checkout.

Ascension Peptides is a third-party research compound vendor. We earn a commission if you purchase through our link, at no cost to you. All compounds are sold for research purposes only.

Get 50% off at Ascension Peptides

Research Protocols & Common Usage

Doses used in research

Research studies have used 200–300mcg per injection
Community protocols commonly report 200–300mcg per injection, typically 1–3x daily, often before sleep and/or training

Administration routes studied

Subcutaneous injection

Typical protocol duration

Research studies have run 8–12 weeks. Community protocols commonly report 3–6 month cycles with breaks.

Common stacking protocols

Ipamorelin + CJC-1295 — the most widely studied and reported GHRP/GHRH combination
Ipamorelin + BPC-157 or TB-500 — combined in recovery-focused protocols

Contraindications & combinations to avoid

Active cancer or personal/family history of certain cancers — GH elevation may be a concern; consult an oncologist
Diabetes or insulin resistance — GH peptides can affect insulin sensitivity; blood glucose monitoring is advisable
Should not be combined with other GHRPs such as GHRP-2 or GHRP-6 — redundant mechanism
Pituitary disorders — consult an endocrinologist

Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.

Considering stacking?

See the stacking guide for common combinations with Ipamorelin and what to avoid.

Stacking guide

Track your Ipamorelin protocol

Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.

Start tracking

Get research updates

We'll notify you when we update the Ipamorelin page or publish related research.

Community Reviews

Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.